On September 3, 2025, Galvanize Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, announced that it has raised $100 million in an oversubscribed Series C financing. The round was led by Sofinnova Partners, with participation from a global syndicate of top-tier investors including Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Janus Henderson Investors, and Longaeva. Existing investors Fidelity Management & Research Company, T. Rowe Price, Gilmartin Capital, Intuitive Surgical, and Apple Tree Partners (ATP), the company's founding investor, also participated in the round. Wilson Sonsini Goodrich & Rosati advised Galvanize on the transaction. The proceeds from the financing will be used to expand the company's commercial footprint and advance its clinical and development activities related to Aliya® PEF in solid tumors and RheOx® therapy for chronic bronchitis.

The Wilson Sonsini team that advised Galvanize on the transaction included:

Corporate
Jason Skolnik
Kassandra Castillo
Bridget Balisy
Dante Matera

Intellectual Property
Maya Skubatch
Darby Chan
Madeline Hess

For more information, please see Galvanize’s news release.